Table 2.

Univariate and multivariate analysis of MRC and clinicopathological factors in all three clinical cohorts

	Cohort 1				Cohort 2				Cohort 3
	Univariate		Multivariate		Univariate		Multivariate		Univariate		Multivariate
	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)
Age (<65 vs >65)	NA	NA	NA	NA	0.40	1.32 (0.69–2.51)			0.35	0.74 (0.39–1.4)
Gender (M vs. F)	0.06	2.32 (0.99–5.45)			0.61	1.17 (0.64–2.16)			0.53	0.82 (0.44–1.53)
Location	0.19	2.62 (0.62–11.06)			0.64	0.85 (0.43–1.69)			0.11	0.49 (0.23–1.06)
Differentiation	0.89	0.87 (0.12–6.4)			0.80	0.86 (0.26–2.77)			0.87	1.09 (0.39–3.07)
T4 vs. T2&3	0.06	2.10 (0.97–4.53)			0.08	1.74 (0.94–3.25)			0.19	1.61 (0.79–3.3)
Tumor Size	0.84	1 (0.98–1.02)			0.72	1 (0.99–1.02)			0.46	1 (0.99–1.01)
Venous Invasion	0.19	1.78 (0.76–4.18)			0.37	1.71 (0.53–5.53)			0.16	2.79 (0.67–11.56)
Lymphatic Invasion	0.01	2.58 (1.22–5.46)	0.14	1.82 (0.82–4.07)	0.68	1.14 (0.62–2.1)			0.01	2.43 (1.24–4.79)	0.12	1.83 (0.84–3.99)
Stage (III vs II)	0.03	2.56 (1.09–6.02)	0.23	1.75 (0.7–4.39)	0.02	2.16 (1.16–4.03)	0.03	2.01 (1.07–3.74)	0.06	1.85 (0.97–3.51)	0.44	1.33 (0.64–2.78)
CEA (Low vs High)	0.90	0.95 (0.43–2.1)			0.10	1.67 (0.91–3.06)			0.60	1.19 (0.63–2.23)
Lymph Node Number	0.18	0.54 (0.22–1.33)			0.64	1.22 (0.54–2.74)			0.13	0.55 (0.25–1.2)
Adjuvant Chemotherapy	0.35	1.43 (0.68–2.99)			0.61	0.85 (0.45–1.6)			0.22	1.48 (0.79–2.75)
MSI	0.81	0.78 (0.10–5.79)			0.16	0.04 (0–3.65)			0.53	0.63 (0.15–2.62)
miRNA classifier	0.001	3.44 (1.56–7.45)	0.01	2.54 (1.29–4.99)	0.0001	6.15 (3.33–11.35)	0.00004	5.11 (2.26–11.53)	0.0003	4.23 (2.26–7.92)	0.00001	3.94 (1.64–9.43)

M, male; F, female; MSI, microsatellite instability; CEA, carcinoembryonic antigen; HR, hazards ratio; CI, confidence interval